Johnson & Johnson, a pharmaceutical, and medical technologies corporation, agreed to acquire Shockwave Medical, a provider of innovative intravascular lithotripsy technology for the treatment of calcified CAD and PAD, for $13.1bn. “With our focus on Innovative Medicine and MedTech, Johnson & Johnson has a long history of tackling cardiovascular disease – the leading cause of death globally. The acquisition of Shockwave and its leading IVL technology provides a unique opportunity to accelerate our impact in cardiovascular intervention and drive greater value for patients, shareholders and health systems,” Joaquin Duato, Johnson & Johnson Chairman and CEO.